Lucid Diagnostics(LUCD) - 2025 Q4 - Earnings Call Presentation

Nasdaq: LUCD Q4 2025 Business Update March 26, 2026 Lishan Aklog MD Dennis McGrath Chairman & CEO CFO Disclaimer 2 4 – 4Q25 EsoGuard test volume: 3,664 – 4Q25 Revenue: $1.5M – Awarded U.S. Department of Veterans Affairs (VA) contract for EsoGuard, expanding access across the nation's largest integrated healthcare system – Announced positive data from the largest reported real-world experience of esophageal precancer detection, evaluating EsoGuard and EsoCheck in nearly 12,000 at-risk patients Business Updat ...